LAVAL, Quebec-- (BUSINESS WIRE)--Altasciences, a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development from lead candidate selection to proof of concept, announced today that they have entered into an agreement to support WuXi AppTec’s Investigational New Drug (WIND) platform. WIND combines world-class CRO services with cross-functional program management and global regulatory expertise to support IND applications. WuXi Clinical, the clinical CRO arm of WuXi AppTec, will be responsible for managing the partnership and ensuring a seamless experience.
Altasciences will provide its full-service solutions, including clinical pharmacology, first-in-human and proof-of-concept trials, program management, medical writing, biostatistics, and data management to support and conduct comprehensive early phase clinical services for WuXi AppTec’s multiple ongoing WIND programs.
“WuXi AppTec and Altasciences share the same vision, which is to provide a seamless, integrated transition from one key milestone to the next during the early phases of drug development. I am confident that together, we will continue on our path to help sponsors research and develop potentially life-saving therapeutics, faster,” stated Chris Perkin, CEO, Altasciences.
With integrated capabilities in toxicology, DMPK, pharmacology, CMC, and analytical services, WuXi AppTec supports the full scope of drug development programs, from IND-enabling studies to regulatory support for both pre-IND and post-IND stages, as well as document preparation and submission.
“Altasciences has strong expertise and deep experience in early phase clinical research. The partnership is an excellent complement for WuXi to help our global collaborators to expedite the R&D process from pre-IND to clinical stages and bring better therapies to patients far faster,”said Edward Hu, Co-CEO, WuXi AppTec.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.